Results 101 to 110 of about 1,253,674 (265)

Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19

The Lancet Respiratory Medicine, 2020
HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or ...
A. Alanio, S. Dellière, S. Fodil, S. Bretagne, B. Mégarbane   +4 more
semanticscholar   +1 more source

Host immune collapse in influenza‐associated pulmonary aspergillosis: From barrier dysfunction to metabolic paralysis

Clinical and Translational Discovery, Volume 6, Issue 3, June 2026.
From barrier dysfunction to metabolic paralysis: IAPA progression is characterized by a functional dissociation: the host experiences hyper‐inflammatory cytokine storms (IL‐1β, IFN‐λ) while simultaneously suffering from antimicrobial metabolic paralysis (loss of ROS and recognition). This creates a specific window for host‐directed therapies, including
Liangyu Li, Shuo Liang
wiley   +1 more source

Pulmonary Aspergillosis: An Evolving Challenge for Diagnosis and Treatment

Infectious Diseases and Therapy, 2020
Aspergillus is a mold that may lead to different clinical pictures, from allergic to invasive disease, depending on the patient’s immune status and structural lung diseases.
Alessandro Russo, Giusy Tiseo, Marco Falcone, Francesco Menichetti   +3 more
doaj   +1 more source

Invasive pulmonary aspergillosis in the COVID‐19 era: An expected new entity

Mycoses (Berlin), 2020
Information on the recently COVID‐19‐associated pulmonary aspergillosis (CAPA) entity is scarce. We describe eight CAPA patients, compare them to colonised ICU patients with coronavirus disease 2019 (COVID‐19), and review the published literature from ...
M. Machado, M. Valerio, A. Álvarez‐Uría, M. Olmedo, Cristina Veintimilla, B. Padilla, S. de la Villa, J. Guinea, P. Escribano, M. Ruíz-Serrano, E. Reigadas, R. Alonso, J. Guerrero, J. Hortal, E. Bouza, P. Muñoz   +15 more
semanticscholar   +1 more source

Pulmonary aspergillosis: new horizons [PDF]

, 2016
Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova, The 6th International Medical Congress for Students and Young Doctors, May 12-14, 2016Introduction. Aspergillus species are ubiquitous fungi, their spores being
Rotaru, Ion
core  

Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis

European Respiratory Journal, 2020
The coronavirus disease 2019 (COVID-19) virus caused a wide spectrum of disease in healthy individuals, as well as those with common comorbidities [1].
D. Armstrong-James, J. Youngs, T. Bicanic, A. Abdolrasouli, David W. Denning, Elizabeth M. Johnson, V. Mehra, T. Pagliuca, Brijesh Patel, J. Rhodes, Silke Schelenz, A. Shah, F. L. van de Veerdonk, P. E. Verweij, P. L. White, M. Fisher   +15 more
semanticscholar   +1 more source

How Do I Manage Refractory Invasive Pulmonary Aspergillosis.

BACKGROUND Invasive aspergillosis is associated with significant morbidity and mortality in patients with hematologic malignancies and hematopoietic cell transplant recipients.
Nguyen, M Hong, Sendi, Parham, Alkhateeb, Hassan, Vergidis, Paschalis   +3 more
core   +1 more source

Invasive pulmonary aspergillosis in an immunocompetent patient

, 2011
Aspergillosis is the group of diseases caused by the Aspergillus species, which cause a broad spectrum of disease, ranging from hypersensitivity reactions to direct angioinvasion.
Iliana Samara Hurtado Rendon, Hurtado Rendon, Iliana Samara, Ciubotaru, Ronald L., Pathak, Vikas, Vikas Pathak, Ronald L. Ciubotaru   +5 more
core   +1 more source

A case of invasive pulmonary aspergillosis during treatment for acute exacerbation of interstitial lung disease

Infectious Disease Reports, 2018
Prolonged immunosuppressive therapy is a risk factor for invasive pulmonary aspergillosis. We report a case of a 79-yearold man who underwent immunosuppressive therapy with methylprednisolone and cyclosporine for an acute exacerbation of interstitial ...
Motoi Ugajin, Hisanori Kani
doaj   +1 more source

Is universal CAR T‐cell referral absolutely required for transplant‐ineligible patients with primary refractory or early relapsed DLBCL?

British Journal of Haematology, EarlyView.
Maria Dimou, Theodoros P. Vassilakopoulos   +1 more
wiley   +1 more source